ALK and lung carcinoma: Using scRNA analysis of biopsies from oncogene-defined lung cancers including EGFR mutant and ALK+ cancers, Maynard et al. revealed a transient immunostimulatory effect in lung cancer patients bearing oncogenic RTKs after initial TKI therapy, followed by establishment of an immunosuppressive environment upon progression33.